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Background: Inactivation of the adenomatous polyposis coli (APC) tumor
suppressor protein is responsible for both inherited and sporadic forms of colon
cancer. Growth control by APC may relate to its ability to downregulate 
β-catenin post-translationally. In cancer, mutations in APC ablate its ability to
regulate β-catenin, and mutations in β-catenin prevent its downregulation by
wild-type APC. Moreover, signaling by the protein product of the wnt-1 
proto-oncogene upregulates β-catenin and promotes tumorigenesis in mice. In
a Xenopus developmental system, Wnt-1 signaling was inhibited by Axin, the
product of the murine fused gene. This suggests a possible link between Axin,
the Wnt-1 signaling components β-catenin and glycogen synthase kinase 3β
(GSK3β), and APC.
Results: Human Axin (hAxin) binds directly to β-catenin, GSK3β, and APC in
vitro, and the endogenous proteins are found in a complex in cells. Binding sites
for Axin were mapped to a region of APC that is typically deleted due to cancer-
associated mutations in the APC gene. Overexpression of hAxin strongly
promoted the downregulation of wild-type β-catenin in colon cancer cells,
whereas mutant oncogenic β-catenin was unaffected. The downregulation was
increased by deletion of the APC-binding domain from Axin, suggesting that
APC may function to derepress Axin activity. In addition, hAxin dramatically
facilitated the phosphorylation of APC and β-catenin by GSK3β in vitro.
Conclusions: Axin acts as a scaffold upon which APC, β-catenin and GSK3β
assemble to coordinate the regulation of β-catenin signaling.
Background
The prevalence of mutations in the adenomatous polypo-
sis coli (APC) gene in colon cancers suggests that the loss
of APC function may be a prerequisite to tumor formation
in the colon [1–8]. Precisely how inactivation of APC con-
tributes to tumor progression is unknown, but probably
relates to its ability to downregulate β-catenin. Mutant
APC lacks this activity [9] and, more recently, mutant β-
catenins that are refractory to downregulation by wild-type
APC have been identified in cancers [10,11]. Deregulation
of β-catenin appears relevant to actual human tumors as
high levels of β-catenin have been detected by immuno-
histochemical staining of tumor tissue sections [12]. More-
over, the wnt-1 proto-oncogene promotes murine tumor
progression and also upregulates β-catenin levels in cell
culture [13–16]. Thus, the regulation of β-catenin, which
directly impacts upon cell adhesion, morphology, motility,
and gene transcription, is an important facet of epithelial
cell growth control.
Both APC and glycogen synthase kinase 3β (GSK3β) have
been implicated in the regulation of β-catenin in mam-
malian cells. APC is phosphorylated by GSK3β in vitro in a
region of the protein that is essential for its ability to
downregulate β-catenin levels [17]. This phosphorylation
also greatly increases the binding affinity of β-catenin for
APC. GSK3β has also been reported to phosphorylate β-
catenin at serine and threonine residues that are critical for
the rapid turnover of β-catenin in the cell [18]. The
premise for examining GSK3β as a regulator of β-catenin
was largely derived from developmental studies in
Xenopus and Drosophila [18–23]. In these systems, the
Wnt-1/Wingless signaling pathway suppresses
GSK3β/Zeste-white 3 activity leading to a transcriptional
output mediated by the effector protein β-
catenin/Armadillo. A recent study in Xenopus identified
Axin as a new potential component of the regulation of β-
catenin signaling [24]. It was shown that murine Axin, the
product of the mouse fused gene, inhibited the dorsal axis
formation in Xenopus that is normally observed on expres-
sion of Wnt-1. Here, we have examined the role of human
Axin (hAxin) in the regulation of β-catenin in cancer cells.
We have found that hAxin contains independent binding
sites for APC, β-catenin, and GSK3β, and that overexpres-
sion of hAxin in cancer cells post-translationally down-
regulates β-catenin.
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Results
A hAxin cDNA was isolated from a fetal brain cDNA
library. This cDNA encoded a polypeptide initiating at the
ninth amino acid with respect to a previously reported
human Axin clone [24] and terminating at amino acid 900
and has therefore been designated hAxin9–900. To deter-
mine whether hAxin would bind directly to β-catenin,
GSK3β, or APC, radiolabeled full-length hAxin and frag-
ments of hAxin were produced by in vitro transcription and
translation in wheat germ lysate and tested for binding to
the purified bait proteins APC2, β-catenin, GSK3β and
APC3. The central region of the APC protein, designated
APC2 and representing amino acids 1034–2130, β-catenin,
and GSK3β all associated with hAxin, whereas only low-
level, non-specific binding was detected with the carboxy-
terminal fragment of APC, termed APC3 and containing
amino acids 2130–2843 (Figure 1a). The background
signal observed with APC3 was comparable to that
observed using purified Rap1 GTPase activating protein
as an additional negative control (data not shown). Dele-
tion of amino acids 9–320 of hAxin, which contains the reg-
ulator of G-protein signaling (RGS) domain [24],
eliminated binding to APC2, but not to β-catenin or
GSK3β. None of these bait proteins associated with the
hAxin fragments 513–900 or 749–900, whereas all three
associated with hAxin9–528. To demonstrate the direct
binding of the hAxin RGS domain to APC, the APC2 frag-
ment was produced in wheat germ lysate and tested for
binding to a purified GST–hAxin84–262 fusion protein.
Radiolabeled APC2 was recovered with
GST–hAxin84–262 protein on glutathione agarose beads
but no APC2 was recovered on beads alone (Figure 1b).
GST–hAxin84–262 did not associate with either β-catenin
or GSK3β in this assay (data not shown). These results
indicate that β-catenin, GSK3β and APC bind directly to
the amino-terminal half of hAxin.
The binding interactions were also observed when Myc-
tagged hAxin was expressed in 293 cells and anti-Myc
immunoprecipitates were analyzed for β-catenin and APC
(Figure 2a). Wild-type APC co-immunoprecipitated with
hAxin fragments corresponding to amino acids 9–900,
84–262 and 9–528. Very little β-catenin was associated
with hAxin9–900 and hAxin9–528 despite their association
in vitro. This was also the case for wild-type APC
(Figure 2a, anti-APC2), however, and may be due to the
low levels of free β-catenin contained in these cells. By
contrast, β-catenin, but not APC, co-immunoprecipitated
with hAxin321–750, which lacks the RGS domain. No
association of APC or β-catenin was seen with
hAxin749–900 or hAxin513–900. Low levels of β-catenin
were detected in the immunoprecipitates of hAxin84–262,
but this may have resulted from its indirect association
through APC. We therefore determined whether β-catenin
could simultaneously bind to the Axin RGS domain and
APC. Purified GST–hAxin84–262 was incubated with
purified β-catenin in the presence or absence of purified
APC2 and then recovered on glutathione–agarose beads.
Analysis of the recovered GST–hAxin84–262 revealed that
the association of β-catenin was dependent upon APC2
and that the amount of β-catenin relative to APC2 was
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Figure 1
In vitro binding of hAxin to APC, β-catenin (β-cat) and GSK3β. (a) The
indicated hAxin constructs were expressed as 35S-labeled proteins by
in vitro transcription and translation in wheat germ lysate and then
incubated with the indicated Glu–Glu epitope-tagged bait proteins.
Bait proteins were recovered by anti-Glu–Glu immunoprecipitation and
analyzed by SDS–PAGE and autoradiography. The lysate sample
represents 20% of that used in the binding analysis. DSH; Dishevelled
homology domain. (b) Radiolabeled APC2 was produced by in vitro
transcription and translation in wheat germ lysate and incubated with
2 µg purified GST–hAxin84–262 fusion protein: hAxin84–262 was
recovered on glutathione–agarose beads and analyzed by SDS–PAGE
and fluorography. Glutathione–agarose beads (GSH–agarose), in the
absence of GST–hAxin84–262, were used a negative control.
Ly
sa
te
A
P
C
2
β-c
at
G
S
K
3β
A
P
C
3
RGS DSH9 900
RGS9 750
321 750
DSH 900513
DSH 900749
RGS9 528
Axin construct
Current Biology
Bait protein
(b)
Ly
sa
te
G
S
H
–a
ga
ro
se
APC2
hA
xi
n8
4–
26
2
(a)
comparable to that observed by direct immunoprecipita-
tion of APC2 (Figure 2b). Fragments of hAxin were also
expressed in the SW480 colorectal carcinoma cell line to
investigate their association with GSK3β. Because detec-
tion of GSK3β in immunoprecipitates is obscured due to
the co-migration of GSK3β with immunoglobulin G heavy
chain, we assayed the immunoprecipitates for GSK3β
activity (Figure 2c). Specific GSK3β activity was associ-
ated with the hAxin fragments 9–900, 9–750, 321–900,
321–750 and 9–528 but not with fragments 513–900,
84–262 and 749–900.
Analysis of the APC gene in colon cancer has delineated a
mutation cluster region in which the majority of the
polypeptide chain-terminating mutations are localized
[25,26]. The 3′ border of this region resides approxi-
mately at codon 1500 and may demarcate the minimal
deletion of corresponding amino acid sequence that is
required to compromise the tumor suppressor activity of
APC. To correlate this mutational border with Axin
binding, we tested binding in a yeast two-hybrid assay
with a series of APC polypeptides that progressively tra-
verse the border of the mutation cluster region
(Figure 3a). We first tested three large APC fragments
that encompass the entire 2843 amino-acid polypeptide
chain. The central APC fragment containing amino acids
957–2130 reacted with hAxin whereas the amino-terminal
and carboxy-terminal fragments corresponding to amino
acids 1–1210 (APC1) and 2130–2843 (APC3), respec-
tively, did not. Subdivision of the central region of APC
revealed that an Axin-binding site resided between APC
amino acids 1554 and 1698, located near the carboxy-ter-
minal border of the mutation cluster region. APC frag-
ments that began after amino acid 1698 also interacted
with hAxin, revealing the presence of more than one
Axin-binding site in the central region of APC.
The results suggest that Axin binding is selected against
by the polypeptide truncations resulting from mutations
in the APC gene in cancer. The mutant APC in the
SW480 colorectal cancer cell line is known to be truncated
at codon 1337 [27] and thus should not associate with the
APC-binding fragment of hAxin. Indeed, expression and
recovery of the hAxin84–262 fragment in SW480 cells
demonstrated that the mutant APC was not associated
with this fragment of hAxin (Figure 3b). This is in contrast
to the association of hAxin84–262 with wild-type APC
from the 293 human embryonic kidney cell line
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In vivo binding of hAxin to APC, β-catenin and GSK3β. (a) The hAxin
constructs were transiently transfected into 293 cells and the
expressed proteins recovered by immunoprecipitation via an encoded
Myc epitope tag. The immunoprecipitates were examined by
SDS–PAGE and immunoblotting for the presence of APC and β-
catenin. The upper panel shows the anti-Myc blot and the lower panel
the anti-Myc immunoprecipitation. Molecular weights in kDa of
standard proteins are indicated to the left of the upper panel.
(b) Purified β-catenin (100 ng) was incubated with 2 µg purified
GST–hAxin84–262 in the absence (– APC2) or presence (+ APC2) of
0.5 µg purified APC2. GST–hAxin84–262 was recovered on
glutathione–agarose and APC2 was immunoprecipitated with anti-
APC2 antibody. Protein-A–Sepharose (PAS) was used as a negative
control and the lane marked input represents 10% of the total reaction
mixture. Precipitates were analyzed by immunoblotting with antibody to
APC (upper panel) and β-catenin (lower panel). (c) The hAxin
constructs were expressed in SW480 cells and the proteins were
recovered as in the legend to (a). Each immunoprecipitate was divided
in half and assayed for GSK3β activity using the specific peptide
substrate P-CREB or the non-specific control peptide NP-CREB; both
peptide substrates are derived from the cAMP-response-element-
binding protein (CREB). Anti-GSK3β indicates direct
immunoprecipitation of GSK3β from control lysate, and 2 ng purified
GSK3β was assayed as a positive control. The inset shows an anti-
Myc immunoblot of the cell lysates where lanes 1–9 represent vector
through hAxin749–900, in the same order as for the histogram.
(Figure 2a). Interestingly, the mutant APC from SW480
cells was co-immunoprecipitated with the hAxin321–900
fragment. As SW480 cells contain an ample supply of free
β-catenin to which the mutant APC can bind, it is likely
that the mutant APC was indirectly associated with
hAxin321–900 through the simultaneous association of
these proteins with β-catenin.
The interaction of hAxin with both APC and β-catenin,
together with the previous finding that Axin inhibited
Wnt-1 signaling in Xenopus [24], prompted us to examine
the effect of Axin expression on the intracellular levels of
β-catenin. Immunofluorescence staining of endogenous 
β-catenin was analyzed in SW480 cells following overex-
pression of hAxin9–900 or, as a positive control, the
APC25 fragment comprising amino acids 1342-2075 of the
APC protein (Figure 4). The transient transfection effi-
ciency in these cells is greater than 50% [9], and a high
percentage of cells exhibited a marked diminution of 
β-catenin immunofluorescence staining following trans-
fection with either hAxin9–900 or APC25. Surprisingly,
hAxin321–900, which lacks the APC-binding domain, also
strongly downregulated intracellular β-catenin. Additional
experiments involving quantitative immunoblotting indi-
cated that hAxin321–900 was a more potent downregulator
of β-catenin than hAxin9–900 (data not shown). This was
also apparent from pulse-chase experiments in which
hAxin was co-expressed with Myc-tagged β-catenin in
SW480 cells and the rate of β-catenin turnover was exam-
ined (Figure 5). The half-life of the Myc–β-catenin was
approximately 90 minutes when co-expressed with
hAxin9–900 compared with a half-life of several hours
when co-expressed with vector control. The half-life was
reduced further to approximately 45 minutes upon co-
expression of hAxin321–900. The half-life of the β-catenin
mutant S37A, which contains a serine to alanine mutation
at amino acid 37 and has previously been shown to be
refractory to APC-dependent turnover [11], was unaf-
fected by hAxin9–900. The results demonstrate that
hAxin downregulates β-catenin in a post-translational
manner and that deletion of the APC-binding domain of
hAxin does not ablate this activity but instead might even
enhance it.
To demonstrate that endogenous Axin was associated with
APC, β-catenin and GSK3β, antibodies specific to Axin
were raised in rabbits. Immunoprecipitates obtained with
affinity-purified antibodies to Axin, APC, GSK3β and β-
catenin were examined by immunoblotting for the pres-
ence of Axin (Figure 6a). A strongly reactive band
co-migrating with purified recombinant hAxin9–900 was
detected in the Axin immunoprecipitates from HCT116
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Figure 3
Localization of Axin-binding sites on APC. (a) Yeast were
cotransformed with one plasmid encoding the indicated APC fragment
fused to the GAL4 DNA-binding domain and another encoding
hAxin84–726 fused to the GAL4 transactivation domain. The presence
of two plasmids permits growth in selective media (Growth) and a
positive APC–Axin interaction produces β-galactosidase detected by
color development (β-Gal). The central region of APC is depicted
schematically where open and closed rectangles represent the 15 and
20 amino acid repeat sequences, respectively, and MCR denotes the
mutation cluster region. (b) Empty vector, hAxin84–262, or
hAxin321–900 were transfected into SW480 cells and the proteins
recovered by immunoprecipitation with Myc antibody (anti-Myc IP).
Immunoprecipitates were analyzed by immunoblotting with antibodies
to APC (upper panel) or β-catenin (lower panel). Mut APC indicates
the endogenous truncated APC protein present in SW480 cells.
colorectal carcinoma cells. A reactive polypeptide of equiv-
alent mobility was also detected in the APC, β-catenin and
GSK3β immunoprecipitates, but not in the anti-Rap1 and
anti-BRCA1 control immunoprecipitates. To assess
whether active GSK3β was associated with endogenous
Axin, GSK3β assays were performed on Axin immunopre-
cipitates (Figure 6b). Anti-Axin immunoprecipitates from
the HCT116 and SW480 cells phosphorylated the specific,
but not the non-specific, GSK3β peptide substrate. These
results indicate that endogenous Axin exists in a complex
with APC, β-catenin and active GSK3β.
The finding that the phosphorylation of APC by GSK3β
greatly enhanced its ability to bind β-catenin led to the
proposal that GSK3β played a role in the regulation of 
β-catenin by APC [17]. In these experiments, GSK3β was
unable to phosphorylate APC efficiently unless prephos-
phorylation of APC was first performed using protein
kinase A. The binding of both GSK3β and APC to Axin
suggests that Axin may serve to facilitate the phosphoryla-
tion of APC by GSK3β. To test this proposal, we per-
formed phosphorylation of APC by GSK3β in the
presence or absence of purified hAxin9–900. The purified
APC fragment APC25 was used in this assay and was
dephosphorylated and repurified as previously described
[17]. In the presence of GSK3β alone, a low level of
APC25 phosphorylation was detected; however, APC25
phosphorylation was dramatically increased on inclusion of
hAxin9–900 (Figure 7). In the absence of GSK3β, low
levels of APC25 phosphorylation were still observed on
inclusion of hAxin9–900, suggesting the presence of a
kinase in the hAxin9–900 preparation. However, the level
of APC25 phosphorylation detected in the presence of
both GSK3β and hAxin9–900 was far greater than the sum
of the phosphorylations observed by GSK3β and
hAxin9–900 alone. Moreover, only when both hAxin9–900
and GSK3β were included did APC25 undergo a bandshift
indicative of quantitative phosphorylation (Figure 7).
These results suggest that Axin greatly enhances the
phosphorylation of APC by GSK3β in vitro. 
While this paper was under review a report by Ikeda et al.
[28] showed that Axin facilitated the phosphorylation of 
β-catenin by GSK3β. Indeed, the inclusion of hAxin9–900
also appears to enhance the phosphorylation of β-catenin
by GSK3β, confirming the findings of Ikeda et al. [28]. 
Discussion
Our results indicate that hAxin is intimately involved in the
process of β-catenin regulation. It binds to the Wnt-1 sig-
naling components β-catenin and GSK3β and strongly
downregulates β-catenin when overexpressed in cancer
cells. The binding of hAxin to both APC and GSK3β is
consistent with a previous report describing a multimolecu-
lar complex containing APC, β-catenin and GSK3β [17]; in
that report, APC was shown to be phosphorylated by
GSK3β in a region of the protein essential for its ability to
downregulate β-catenin. Here, we found that the phospho-
rylation of APC in vitro by GSK3β is enhanced by the
inclusion of hAxin protein. In a separate study it was shown
that GSK3β also phosphorylated β-catenin at serine and
threonine residues known to be critical for its turnover [18].
Ikeda et al. [28] have recently reported that Axin facilitates
this phosphorylation and our data are also in agreement
with their finding. Thus, the binding of APC and β-catenin
to Axin may serve to establish a local proximity and orienta-
tion that facilitates their phosphorylation by GSK3β in vivo
(Figure 8). Moreover, the association of both GSK3β and
APC with Axin provides an explanation for a previously
described multimolecular complex containing APC and
GSK3β [17]. Although this complex could be demonstrated
using cell lysates, we were unable to observe direct binding
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Figure 4
Downregulation of β-catenin. SW480 cells
were transiently transfected with APC25,
hAxin9–900, hAxin321–900, or vector control
and endogenous β-catenin was visualized by
immunofluorescence staining (IF). The same
image was then recorded in the presence of
both fluorescent and visible light (IF + visible).
APC25 hAxin321–900 hAxin9–900 Vector
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of GSK3β to either β-catenin or APC using purified pro-
teins or using the yeast two-hybrid interaction assay (our
unpublished observations). Thus, Axin provides the
missing link for the connection of APC to GSK3β.
The phenotype observed on expression of the full-length
hAxin9–900 in mammalian cells agrees with that observed
for ectopic expression of murine Axin in Xenopus develop-
ment [24]. We found that hAxin downregulated β-catenin
and Zeng et al. [24] reported that Axin inhibited β-catenin
cell signaling in Xenopus. It is thought that GSK3β nega-
tively regulates β-catenin in this signaling pathway, as
expression of a dominant-negative form of GSK3β
resulted in a positive signal [22,29]. The expression of 
β-catenin, but not dominant-negative GSK3β, overcame
the inhibition by Axin, leading Zeng et al. [24] to conclude
that Axin acted upstream of β-catenin and downstream of
GSK3β in the Wnt-1 pathway. However, our results
showing direct binding of GSK3β to hAxin suggest that
578 Current Biology, Vol 8 No 10
Figure 5
Pulse-chase analysis of ectopically expressed wild-type (wt) β-catenin
and the S37A β-catenin mutant. SW480 cells were transiently
cotransfected with the indicated plasmids, pulse-labeled with 
35S-methionine, and then chased with cold media. At the indicated
times, cells were lysed and the expressed β-catenin was recovered by
immunoprecipitation via a Myc epitope tag fused to the β-catenin
protein. (a) Analysis of immunoprecipitates by SDS–PAGE and
fluorography. (b) Expression levels of the Glu–Glu-tagged hAxin
fragments detected by anti-Glu–Glu immunoblotting of a normalized
lysate aliquot. (c) Plot of the pulse-chase analysis quantitated by 
β-scanning.
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Figure 6
Association of endogenous hAxin with APC, β-catenin and GSK3β.
(a) Whole cell lysates from HCT116 and SW480 cells were subjected
to immunoprecipitation with antibodies specific to Axin, APC, β-
catenin, GSK3β or, as controls, Rap1 and BRCA1. The
immunoprecipitates were analyzed by SDS–PAGE and immunoblotting
with anti-Axin antibody. Approximately 20 ng purified recombinant
hAxin9–900 was loaded as a positive control. Molecular weights in
kDa of standard proteins are indicated to the left. (b)
Immunoprecipitates of endogenous Axin, GSK3β or Rap1 from whole
cell lysates from HCT116 and SW480 cells were assayed for GSK3β
activity. Purified GSK3β (2 ng) was used as a positive control.
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dominant-negative GSK3β may operate simply by displac-
ing wild-type GSK3β from Axin. This may not have been
observed in Xenopus if the level of ectopically expressed
dominant-negative GSK3β did not substantially exceed
that of the ectopically expressed Axin.
A more curious departure from the Xenopus study is appar-
ent when comparing the effects of a deletion mutant of Axin
that lacks an RGS domain. In mammalian cells, this mutant
resulted in enhanced downregulation of β-catenin, whereas
a similar protein promoted, rather than inhibited, β-catenin
signaling in Xenopus [24]. The effect of Axin on the levels of
β-catenin in the Xenopus system were not determined,
however, and β-catenin levels in Xenopus may not be
affected by Axin in the same way as is observed in mam-
malian cells. Manipulation of the Wnt-1 pathway in Xenopus
has also led to paradoxical conclusions regarding the role of
APC. Expression of wild-type APC in mammalian cells pro-
motes the downregulation of β-catenin [9], whereas forced
expression of wild-type APC in Xenopus results in positive 
β-catenin signaling [30]. The contrasts in mammalian and
Xenopus signaling may indicate differences in the utilization
of the Wnt-1 signaling components between these organ-
isms. Indeed, Wnt-1 signaling components identified in
Caenorhabditis elegans do not appear to operate in a similar
manner as that described for these components in either
Xenopus or mammalian cells [31]. Alternatively, differences
in the experimental paradigms used to study the signaling
pathways could account for the different outcomes.
In a previous study, we reported that the polypeptide
chain-terminating mutations that are characteristic of the
forms of APC associated with cancer progression correlate
well with the loss of the downregulatory activity of APC
on β-catenin [32]. It was concluded that a defined
number of tandemly repeated amino acid sequences in
the central region of APC were required for its ability to
downregulate β-catenin. The present study, however,
shows that the loss of this activity may instead relate to
the inability of mutant APC to associate directly with cel-
lular Axin. If association with Axin is required for APC
tumor suppressor activity, it might be expected that Axin
itself would be deleted or mutated in some cancers. This
may not be the case for the SW480 or HCT116 colon
cancer cell lines, as indicated by immunoblotting, as
these cells already contain mutant APC and mutant 
β-catenin, respectively [10]. Interestingly, overexpression
of hAxin promoted the downregulation of β-catenin in
SW480 cells, despite the lack of wild-type APC expres-
sion in these cells. This suggests that endogenous levels
of Axin are not sufficient to regulate β-catenin in the
absence of wild-type APC and that Axin overexpression
may compensate for this by mass action. Indeed, hAxin
may not require APC as removal of its APC-binding
domain did not impair its ability to regulate β-catenin,
but instead increased it. Thus, APC may serve to dere-
press Axin by binding a regulatory domain that normally
inhibits the ability of Axin to downregulate β-catenin.
Conclusions
Human Axin associates with the APC tumor suppressor
protein at binding sites in the APC protein that are
deleted due to cancer-causing mutations. Axin probably
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Figure 7
Axin facilitates phosphorylation of APC and β-catenin in vitro. Purified
proteins produced using the baculovirus/Sf9 cell expression system
were combined as indicated and incubated in the presence of 
[γ-32P]ATP. Autoradiography (upper panel) was performed following
SDS–PAGE and electroblotting. Immunoblotting for APC and β-
catenin was performed on 5% of each reaction mixture (lower panel).
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Figure 8
Proposed interaction of Axin with APC, β-catenin and GSK3β. Axin
interacts simultaneously with GSK3β, APC, and β-catenin, thereby
promoting the phosphorylation of the latter two proteins by GSK3β
(represented by red arrows). The interaction leads to the rapid
degradation of β-catenin in the cell.
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plays a critical role in the downregulation of β-catenin by
APC. The binding of β-catenin and GSK3β to Axin sug-
gests that Axin assembles the protein components that are
required for β-catenin degradation into a closely associated
complex. The inability of APC to participate in this
complex may lead to deregulated β-catenin signaling that
then contributes to tumor progression.
Materials and methods
Plasmids and cell lines
A hAxin cDNA (Genbank accession number AF009674) was cloned
from a human fetal brain cDNA library (Stratagene). A 1.9 kb PCR
product was generated using the following primers: GGGAAAGGT-
GTTGGCATT and GTGGGGTCTTGGATGAAGA. Two radiolabelled
cDNA probes were generated using this PCR product as a template
and the following primer sets: GGGAAAGGTGTTGGCATT and
TCGTTCGAGTCACAGGGC and AACGCCAGTGATGGCCTC and
GTGGGGTCTTGGATGAAGA. A cDNA encoding hAxin initiating at
amino acid 9, with respect to the published sequence [24], and termi-
nating at amino acid 900 was isolated. This cDNA does not include the
36 amino acid insert previously shown to be present in human form 2
[24]. In addition, we noted three differences in our cDNA sequence
which affect the amino acid sequence. One of these occurred at codon
397 (GCC to GTG) changing alanine to valine, one occurred at codon
520 (ACT to CCT) changing threonine to proline, and finally three
nucleotides contained between codons 488 and 493 were absent
from our sequence resulting in an in-frame deletion of alanine 493 and
the following change in amino acid sequence; 488LCWTW492 to
488CVDMG492. The new amino sequence is now identical to the
mouse sequence, indicating that the original human sequence [24]
was probably an error. These cDNAs were subcloned into the
pCDNA3 (Invitrogen) expression vector containing a Myc epitope tag:
hAxin9–900 was subcloned as an EcoRI–XbaI fragment; hAxin9–750
was subcloned as an EcoRI–(AscI, blunt) fragment into the
EcoRI–EcoRV sites; hAxin321–750 was subcloned as an AccI frag-
ment into the EcoRV site; hAxin513–900 was generated by subcloning
a PCR product into the EcoRI–XbaI sites; hAxin749–900 was sub-
cloned as an (AscI, blunt)–XbaI fragment into the EcoRV–XbaI sites;
hAxin9–528 was made by subcloning a PCR product into the
EcoRI–XbaI sites; hAxin321–900 was subcloned as a AccI fragment
into the EcoRV site; hAxin84–729 was a PCR product generated from
a human fetal brain cDNA library. The PCR product was cloned into the
TA cloning vector and then subcloned as an EcoRI fragment into
pCDNA3; hAxin84–262 was obtained by digestion of hAxin84–729
with BstXI and XbaI, followed by treatment with T4 polymerase and reli-
gation. For expression of hAxin in Sf9 cells, hAxin9–900 was sub-
cloned into pFastBac as an EcoRI–XbaI fragment.
SW480 and HCT116 cell lines were derived from human colorectal
cancers (ATCC references CCL228 and CCL247, respectively), 293
is an immortalized embryonic kidney cell line (ATCC reference
CRL1573).
Antibodies
Polyclonal antibodies to APC2, β-catenin, GSK3β, and monoclonal
antibodies to the Myc and Glu–Glu epitopes have been described
elsewhere [11]. Antibodies to Axin were raised in rabbits against the
purified murine Axin fragment 811–992 fused to GST and produced in
Escherichia coli. The murine cDNA (accession number 464191) was
purchased from Genome Systems and subcloned as a EcoRI–XbaI
fragment into a pGEX vector for expression in E. coli. Antibodies were
affinity-purified against the antigen as described previously [33].
In vitro binding
The bait proteins APC2, β-catenin, GSK3β and APC3 all contained
amino-terminal Glu–Glu epitope tags and were produced using bac-
ulovirus/Sf9 cell expression and then immunoaffinity-purified using
immobilized Glu–Glu antibody. Affinity precipitation of in vitro trans-
lated proteins was performed by first transcribing and translating the
indicated hAxin cDNAs using the wheat germ lysate system (Promega)
in the presence of 35S-methionine according to the manufacturers’
instructions. A 5 µl aliquot of the lysate was diluted to 200 µl in 20 mM
Tris (pH 7.5), 100 mM NaCl, and 1 mM dithiothreitol and incubated
with 2 µg each of the purified bait proteins for 2 h on ice. Bait proteins
were recovered by anti-Glu–Glu immunoprecipitation on protein-
G–Sepharose; after three washes with buffer B (25 mM Tris (pH 7.5),
0.15 M NaCl and 0.1% NP-40), proteins were eluted from the
Sepharose with SDS–PAGE sample buffer and analyzed by
SDS–PAGE and fluorography. The in vitro binding of purified
GST–hAxin84–262 to APC2 produced by in vitro translation was also
performed as described as above for binding of bait proteins to in vitro
translated hAxin fragments. The in vitro binding of purified proteins to
each other was carried out in a final volume of 150 µl 25 mM Tris
(pH 7.5), 50 mM NaCl, 1 mM dithiothreitol, 0.1 mg/ml bovine serum
albumin and 0.1% NP-40. All binding reactions contained 100 ng of β-
catenin and 2 µg GST–hAxin84–262 and incubations were performed
for 30 min at 30°C in the presence or absence of 500 ng APC2.
Protein-A–Sepharose, glutathione–agarose or protein-A–Sepharose
and 2 µg anti-APC2 antibody were added to the reactions, as indi-
cated, followed by a 1 h incubation with rocking at 4°C. The beads
were recovered and washed as described above and the eluted pro-
teins analyzed by SDS–PAGE and immunoblotting. The β-catenin and
APC2 proteins were produced using the baculovirus/Sf9 cell expres-
sion system.
In vivo binding
For expression of hAxin in mammalian cells, 4 µg plasmid was trans-
fected into a 3.5 cm dish of subconfluent SW480 or 293 cells as
described previously [9,34]. Cells were lysed on the dish in 400 µl
lysis buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 2.5 mM MgCl2, 1 mM
dithiothreitol, 0.4% Triton X-100, 25 mM NaF, 1 mM sodium vana-
date, 30 µg/ml leupeptin and aprotinin, and 1 µM pefabloc) 48 h after
transfection and, following centrifugation, the supernatants were incu-
bated with 2 µg antibody specific to the Myc epitope. Immunocom-
plexes were recovered on protein-G–Sepharose, washed three times
with buffer B, and analyzed by SDS–PAGE and immunoblotting as
described previously [33]. Immunoprecipitation of endogenous APC,
β-catenin and GSK3β was carried out as described in [17]. Affinity-
purified Axin antibodies were used at a final concentration of 2 µg/ml
for immunoprecipitation or 0.2 µg/ml for immunoblotting. Western
blots were developed using the ECL system (Amersham). Yeast two-
hybrid binding analysis was carried out as described previously [32].
GSK3β assays were performed as previously described [17] using a
peptide substrate (CREB) which requires prephosphorylation by
protein kinase A (P-CREB) for subsequent phosphorylation by GSK3.
Downregulation of β-catenin
Immunofluorescence detection of β-catenin in fixed whole cells was
carried out as described previously [9]. The transfected SW480 cells
were grown on coverslips, fixed in methanol and stained using mouse
monoclonal antibodies to β-catenin (Transduction Laboratories). Pulse-
chase analysis of β-catenin protein turnover was carried out as
described previously [11]. Each time point was derived from a single
3.5 cm well of SW480 cells pulse-labeled for 30 min with 0.1 mCi
each of 35S-methionine. Cells were lysed on the dish with lysis buffer
and following clarification by centrifugation, the β-catenin was recov-
ered by immunoprecipitation via the Myc epitope tag.
In vitro phosphorylation
Purified proteins were incubated in a final volume of 20 µl 25 mM Tris
(pH 7.5), 10 mM MgCl2, 2 mM dithiothreitol, 50 mM NaCl, 10% glyc-
erol and 50 µM [γ-32P]ATP (10,000 cpm/pmol). Proteins were pro-
duced using the baculovirus/Sf9 cell expression system and the
following amounts were included in the reaction: APC25, 300 ng; β-
catenin, 300 ng; GSK3β, 200 ng; hAxin9–900, 200 ng. Following a
20 min incubation at 30°C, the reactions were terminated by addition
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of SDS–PAGE sample buffer. Autoradiograms were generated from
PVDF filter membranes to which the proteins were electrophoretically
transferred following SDS–PAGE.
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